Nutriband Stock Price, News & Analysis

Nutriband (NASDAQ:NTRB) announced that CEO Gareth Sheridan will temporarily step down for three months to pursue candidacy in the Irish Presidential election. Chairman and President Serguei Melnik will serve as interim CEO during September and October 2025.

The company recently received FDA meeting approval for AVERSA Fentanyl, their abuse-deterrent opioid patch. The product has projected peak annual US sales potential of $80-200 million and is protected by patents in 46 countries. The company remains on track for its planned NDA filing in 2026.

Nutriband (NASDAQ:NTRB) has secured a Type C Meeting with the FDA for its AVERSA™ FENTANYL, a pioneering abuse-deterrent fentanyl transdermal system. The virtual meeting, scheduled for September 18, 2025, will focus on Chemistry, Manufacturing, and Controls (CMC) plans from IND submission through 505(b)(2) NDA approval.

The company is collaborating with Kindeva to combine Nutriband's AVERSA™ abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch. The product aims to be the world's first abuse-deterrent opioid patch, with projected peak annual US sales of $80-200 million. The technology is protected by patents in 46 countries, including major markets worldwide.

Nutriband (NASDAQ:NTRB) has announced key dates for its upcoming 25% preferred stock dividend. Shareholders of record as of July 25th, 2025 will receive one preferred share for every four common shares held, with the distribution set for August 5th.

The preferred shares come with two key features: they will be convertible to common stock upon FDA approval of the company's AVERSA Fentanyl product, and if not converted, shareholders will be entitled to an annual cash dividend from company profits, as determined by the Board of Directors.

Nutriband (NASDAQ:NTRB) has declared a 25% preferred stock dividend, where shareholders will receive one preferred share for every four common shares held as of July 25th, 2025, with distribution set for August 5th. The preferred shares are convertible to common stock upon FDA approval of AVERSA Fentanyl product.

These preferred shares will be eligible for annual cash dividends from company profits if not converted. CEO Gareth Sheridan emphasized the company's focus on shareholder value creation and highlighted recent progress with Kindeva on commercialization manufacturing as they prepare for FDA approval submission.

Nutriband Inc. (NASDAQ:NTRB) has achieved a significant milestone with its inclusion in four Russell indexes: the Russell Microcap Index, Russell Microcap Growth Index, Russell 3000E Index, and Russell 3000E Growth Index as part of the 2025 Russell indexes reconstitution.

CEO Gareth Sheridan highlighted the company's AVERSA pipeline development, particularly AVERSA Fentanyl, which has a projected peak annual US sales potential of $80 million to $200 million. The company aims to enhance the safety profile of easily abused medications while ensuring availability to patients in need.

The Russell indexes, which serve as benchmarks for approximately $10.6 trillion in assets as of June 2024, are widely utilized by investment managers and institutional investors for index funds and active investment strategies. FTSE Russell will transition to a semi-annual reconstitution frequency starting in 2026.

Nutriband (NASDAQ:NTRB) has achieved a significant milestone by completing the commercial manufacturing process scale-up for Aversa™ Fentanyl, its pioneering abuse-deterrent fentanyl patch, in partnership with Kindeva. The product combines Nutriband's Aversa™ abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch, manufactured at Kindeva's U.S.-based transdermal facility. The next phase involves manufacturing clinical supplies and filing an IND application with the FDA for human abuse liability studies. Aversa™ Fentanyl aims to be the first abuse-deterrent pain patch globally, incorporating aversive agents to prevent abuse, diversion, misuse, and accidental exposure of drugs. The technology is protected by patents in 46 countries and has potential peak annual US sales of $80-200 million, with plans for global market expansion.

Nutriband announced the issuance of US patent number 12,318,492 for its AVERSA abuse deterrent transdermal technology. The patent, titled 'Abuse and Misuse Deterrent Transdermal Systems,' strengthens Nutriband's intellectual property protection for its abuse-deterrent transdermal products. AVERSA technology is designed to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential in transdermal patches. The company's intellectual property portfolio now spans 46 countries, including major markets like the US, Europe, Japan, and China. Nutriband's flagship product in development, Aversa Fentanyl, aims to become the first abuse-deterrent pain patch available, with projected peak annual US sales between $80-200 million.

Nutriband Inc. (NASDAQ:NTRB) has announced that CEO Gareth Sheridan will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on June 5th, 2025, at 4PM EST. The presentation will feature a fireside Q&A session with live audience participation. Qualified investor attendees can schedule one-on-one meetings with the company. The presentation will be available for free viewing through registration and will be archived for 90 days on both Nutriband's website and Channelchek.com, Noble's investor portal.

Nutriband Inc. (NTRB) reported strong Q1 2025 financial results, achieving record revenue of $667,000, marking a 63% year-over-year increase. The growth is driven by expanded kinesiology tape production through Pocono Pharma subsidiary, with products now available in major retailers including Target, Walmart, Walgreens, and CVS. The company announced a significant partnership with Kindeva Drug Delivery for AVERSA Fentanyl development, featuring shared development costs and milestone payments. AVERSA Fentanyl aims to be the first abuse-deterrent opioid patch, with potential peak annual US sales estimated between $80-200 million. The product is designed to prevent abuse, misuse, and accidental exposure of transdermal fentanyl patches.